论文部分内容阅读
目的:评定液-质联用法(LC-MS/MS)测定人血浆中卡马西平(CBZ)浓度的不确定度。方法:分析LC-MS/MS法测定人血浆中CBZ浓度的整个过程,确定不确定度的来源和大小,最后进行合成并扩展。结果:人血浆中低浓度(14.8 ng·mL~(-1))和高浓度(717 ng·mL~(-1))CBZ的扩展不确定度分别为0.92 ng·mL~(-1)和38.8 ng·mL~(-1)(P=95%,k=2)。结论:LCMS/MS法测定人血浆中CBZ浓度的不确定度在低浓度时主要由重复性、生物样品配制、基质效应和回收率引入,在高浓度时主要由生物样品配制、基质效应和回收率引入。
OBJECTIVE: To assess the uncertainty of determination of carbamazepine (CBZ) concentration in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS / MS). Methods: The whole process of determination of CBZ concentration in human plasma by LC-MS / MS method was analyzed to determine the source and size of uncertainty and finally to synthesize and expand. RESULTS: The expanded uncertainty of CBZ concentrations in human plasma at concentrations of 14.8 ng · mL -1 and 717 ng · mL -1 were 0.92 ng · mL -1 and 38.8 ng · mL -1 (P = 95%, k = 2). Conclusion: The uncertainty of determination of CBZ concentration in human plasma by LCMS / MS is mainly composed of reproducibility, preparation of biological samples, matrix effect and recovery at low concentration, mainly by biological samples at high concentration, matrix effect and recovery Rate of introduction.